World Health Day: Genome research taking medicine into a new frontier

Big Bang moment

clock • 4 min read
Randall Dishmon of Invesco’s Global Focus Strategy

Randall Dishmon of Invesco’s Global Focus Strategy

Mapping the genome can legitimately be thought of as a Big Bang moment in medicine. The Human Genome Project began in 1990, with a goal of mapping the full human genome by 2005. It was ultimately completed by 2003.

The emergence of the field of genomics put research, drug development and diagnostics on a new and exciting course. We are still in the early stages of this. Why human genome projects are important? A key advancement has been the discovery that several of our most vexing and deadly diseases are caused by genetic mutations. This provides the opportunity to screen and diagnose long before any disease has even manifested.   DNA is an acronym that is often tossed about. It stands for deoxyribonucleic acid. Cutting to the chase, DNA is essentially the recipe for the production of the pro...

To continue reading this article...

Join Investment Week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now


Already an Investment Week


More on Alternatives

Mike Preston, partner at Cleary Gottlieb

Private equity in sport: A growing opportunity

Expected to grow to $500bn

Mike Preston
clock 11 August 2022 • 4 min read
David Coombs, head of multi-asset at Rathbones Unit Trust Management

Rathbones' Coombs: Multi-asset funds 'called it right' but unable to combat hardship

Rathbone Multi-Asset Strategic Growth

clock 05 August 2022 • 3 min read
Alan Gauld, senior investment director at abrdn

abrdn's Gauld weighs tilt towards value-oriented sectors amid market rotation

Value buyouts to represent 30%

clock 29 July 2022 • 2 min read